Dear Americans

Release date: 7/13/2012

Your politicians are owned and operated by Big Pharma. It is so bad that they are attacking Canadian pharmacies who are selling their drugs to Americans at a discount, and soon it will be a federal offense to buy your identical  drugs from them.

Your politicians are owned and operated by Big Pharma. It is so bad that they are attacking Canadian pharmacies who are selling their drugs to Americans at a discount, and soon it will be a federal offense to buy your identical drugs from them. Most of our readers can afford their prescriptions, but most everyone in your govt is working to make that number go down, so “Die, Sucker, because we will jail you if you buy from Canada.” Pharma and your govt DO NOT GIVE A TINKERS DAMM ABOUT YOU.

Many of you resent that statement. So read about a government which actually CARES about suffering patients and says, in effect: “Dear Pharma: Continue to screw American patients by making them pay far more than anyone else, but get your profiteering butts out of our country.”

Healthcare, up til now, was a “luxury” in India. Diabetics are dying because they cannot afford insulin at Pharma’s USA-led profiteering prices. Previous govts were bribed by Pharma to keep it going, but no more!
Under the plan, doctors will be limited to a generics-only drug list and face punishment for prescribing branded medicines, a major disadvantage for pharmaceutical giants in one of the world's fastest-growing drug markets.
Meanwhile, in the USA, the Pharma-owned FDA now allows drug companies to circumvent the law and PREVENT generic drugs. Drug companies, about to lose the patent on a super-profitable drug, actually BRIBE the generic makers NOT to make generics, paying them hundreds of millions so the expired patent holder can continue to make billions from you on their outrageous USA-only prices. So everyone makes money at the expense of the suckers who are hooked on that drug---and the FDA “regulators” laugh all the way to the bank while you go broke.



TWO ARTICLES SHOWING HOW A REAL GOVT, NOT ONE OWNED BY BIG PHARMA, OPERATES. BY HENRY FOY AT REUTERS:

Monday, Mar 19, 2012

Cheap generic drugs were meant to change the life of Nandakhu Nissar, whose mouth is swollen by a cancerous tumor. But the cashless and hungry 55-year-old sleeps on a pavement staring up at the windows of Mumbai's biggest cancer hospital. "What is a generic drug?" shrugs Nissar, who has travelled over 1,500 km (900 miles) from his home in the hope of treatment.

A ruling this week that for the first time allowed an Indian drugmaker to make and sell a blockbuster cancer drug at a fraction of the market price has been hailed as a breakthrough by campaigners for cheaper medicine in the emerging economy. IT WAS A FINE IDEA, BUT NOT ENOUGH TO HELP MILLIONS OF DYING INDIANS---SO….
India to give FREE generic drugs to hundreds of millions----Reuters



By Henry Foy
MUMBAI | Thu Jul 5, 2012 12:00am EDT

(Reuters) - India has put in place a $5.4 billion policy to provide free medicine to its people, a decision that could change the lives of hundreds of millions, but a ban on branded drugs stands to cut Big Pharma out of the windfall. ED NOTE: This could never happen in the USA where every politician and regulator is in on the scam ond only YOU are out!

From city hospitals to tiny rural clinics, India's public doctors will soon be able to prescribe free generic drugs to all comers, vastly expanding access to medicine in a country where public spending on health was just $4.50 per person last year.

The plan was quietly adopted last year but not publicized. Initial funding has been allocated in recent weeks, officials said.

Under the plan, doctors will be limited to a generics-only drug list and face punishment for prescribing branded medicines, a major disadvantage for pharmaceutical giants in one of the world's fastest-growing drug markets.
"Without a doubt, it is a considerable blow to an already beleaguered industry, recently the subject of several disadvantageous decisions in India," said KPMG partner Chris Stirling, who is European head of Chemicals and Pharmaceuticals.

"Pharmaceutical firms will likely rethink their emerging markets strategies carefully to take account of this development, and any similar copycat moves across other geographies," he added.
But the initiative would overhaul a system where healthcare is often a luxury and private clinics account for four times as much spending as state hospitals, despite 40 percent of the people living below the poverty line, or $1.25 a day or less.

Within five years, up to half of India's 1.2 billion people are likely to take advantage of the scheme, the government says. Others are likely to continue visiting private hospitals and clinics, where the scheme will not operate.
"The policy of the government is to promote greater and rational use of generic medicines that are of standard quality," said L.C. Goyal, additional secretary at India's Ministry of Health and Family Welfare and a key proponent of the policy. "They are much, much cheaper than the branded ones."

READ HOW BEFORE LONG THERE WILL BE MORE POOR AMERICANS THAN POOR INDIANS WITHOUT MEDICATIONS.

Global drugmakers like Pfizer, GlaxoSmithKline and Merck will be hit. They spend billions of dollars a year researching new treatments and target huge growth for branded medicine in emerging economies such as India, where generics account for around 90 percent of drug sales by value, far more than in developed countries.
U.S.-based Abbott Laboratories, which bought an Indian generics maker in 2010, is the biggest seller of drugs, both branded and generic, in India, followed by GlaxoSmithKline.

BIG PHARMA BLUES

In March, India granted its first ever compulsory license, allowing a domestic drugmaker to manufacture a copy-cat version of Nexavar, a cancer drug developed by Germany's Bayer, unnerving foreign drugmakers that fear a lack of intellectual property protection in emerging markets.

That enabled India's Natco Pharma to sell its generic version of Nexavar at 8,800 rupees ($160) per monthly dose, a fraction of the 280,000 rupees Bayer's version cost.

In another blow to Big Pharma's emerging market ambitions, China recently overhauled regulations to grant authorities the power to allow domestic drugmakers to produce cheap copies of medicines protected by patents.

Emerging markets are on track to make up 28 percent of global pharmaceuticals sales by 2015, up from 12 percent in 2005, according to IMS Health, a healthcare information and services company.

Most sales in emerging markets come from branded generics, which are off-patent drugs priced at a premium to those made by local manufacturers.

The Organisation of Pharmaceutical Producers of India (OPPI), a lobby group for multinational drugmakers in the country, argues that the price of drugs is just one factor in access to healthcare and that the scheme need not be detrimental to manufacturers of branded drugs.

"I think this will hasten overall growth of the pharmaceutical industry, as poor patients who could not afford will now have access to essential medicines," said Tapan Ray, director general of OPPI.

About 600 billion rupees ($11 billion) in drugs are sold each year in India, or 482 billion at wholesale. Drugs covered under the new policy account for about 60 percent of existing sales, or 290 billion rupees at wholesale cost.
The government's annual cost is likely to be lower due to bulk purchasing and because patients at private clinics would still pay for their own drugs. States will pay for 25 percent of the free drugs and the central government will cover the rest.

Under various existing programs, around 250 million people, or less than a quarter of India's population, now receive free medicines, according to the health ministry.

India's new policy, to be implemented by the end of 2012 and rolled out nationwide within two years, is expected to provide 52 percent of the population with free drugs by April 2017, at a cumulative cost of 300 billion rupees ($5.4 billion).

That requires a major funding ramp-up from a deficit-strapped government. The scheme has been granted just 1 billion rupees thus far from central government coffers.

STRICT INSTRUCTIONS

Public doctors will be able to spend 5 percent of the budget, equivalent to around $50 million a year, on drugs outside of the government's list, on branded drugs or on medicines that are not on the list. Beyond that, they can be punished, said Goyal, the health ministry official.

"If doctors are found to be prescribing medicines which are not on the list, or which are branded, then disciplinary action will be initiated," he said.

Free medicine is just one solution to better healthcare in India, where just getting to a state clinic can require a long journey.

The free generics scheme, which mirrors policies in the states of Tamil Nadu and Rajasthan, is expected to be fully operational by the time voters go to the polls for the 2014 general election, when the populist Congress party will seek a third straight victory.

Indian makers of generics such as Dr Reddy's and Cipla are best placed to benefit.

"The move will please the generics manufacturers who stand to gain substantially in competing for contracts," said KPMG's Stirling.
($1 = 57 Indian rupees)

ED NOTE: You can bet your last dollar that Pharma is desperately looking for someone, anyone, to bribe to stop this from happening. RSCI prays that they don’t find him.

Tip 2: The system stinks to high heaven. Your over-prescribing doctor couldn’t tell you what the side effects he’s pouring down you throat are. But he does know exactly what commissions he earns when he hands you that piece of paper. So start doing what the sharper patients do. Look up EVERY drug you are taking before you buy it. Side effects, effectiveness (especially look for negative articles showing the truth), approvals elsewhere, and the biggest secret of all---deaths.

Most of all, VERIFY THAT IT IS APPROVED FOR YOUR DISEASE and that your MD isn’t listening to the crooks at every drug company pretending that non-approved conditions are treatable with it. The ONLY sure thing is that your MD is making a commission, and that’s all he cares about, certainly not you.